{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T08:35:30Z","timestamp":1794040530445,"version":"4.8.0"},"reference-count":250,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12072-026-11108-1","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T17:28:03Z","timestamp":1782581283000},"page":"911-942","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update"],"prefix":"10.1007","volume":"20","author":[{"given":"Hong","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhi","family":"Maiwall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadir","family":"Dokmeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Gao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Gani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiliang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasmik","family":"Ghazinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Chin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmas Rinaldi A.","family":"Lesmana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosmawati","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Necati","family":"Ormeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyuki","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Payawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pham Thanh","family":"Thuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keo","family":"Sailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj Kumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose D.","family":"Sollano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawesak","family":"Tanwandee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Lai Hung","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng Kiong","family":"Yeoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry Cheuk-Fung","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Lung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Omata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv Kumar","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8928-3769","authenticated-orcid":false,"given":"George","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"APASL Viral Elimination Taskforce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"11108_CR1","unstructured":"WHO, Hepatitis B. 2024; https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b"},{"key":"11108_CR2","unstructured":"World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva, 2024."},{"issue":"2","key":"11108_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12072-024-10744-9","volume":"19","author":"J Chen","year":"2025","unstructured":"Chen J, Jia J, Zhuang H, Zhang W, Yang JM, Tanwandee T, et al. Assessing pricing and affordability of HBV treatment in Asia-Pacific region: a barrier to elimination. Hepatol Int. 2025;19(2):349\u2013357","journal-title":"Hepatol Int"},{"issue":"1","key":"11108_CR4","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1186\/s12879-024-09617-1","volume":"24","author":"M Duan","year":"2024","unstructured":"Duan M, Xiao H, Shi M, Xie Y, Zhao P, Li S, et al. Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT. BMC Infect Dis. 2024;24(1):723","journal-title":"BMC Infect Dis"},{"issue":"10","key":"11108_CR5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2468-1253(25)00053-6","volume":"10","author":"PT Kennedy","year":"2025","unstructured":"Kennedy PT, Allweiss L, Bertoletti A, Cornberg M, Gehring AJ, Guidotti LG, et al. Scientific and medical evidence informing expansion of hepatitis B treatment guidelines. Lancet Gastroenterol Hepatol. 2025;10(10):941\u2013951","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"11108_CR6","unstructured":"Gill US, Appleby VJ, Lens S. \u2018What is new in hepatitis B\u2019. Frontline Gastroenterology 2026;17:161\u2013171"},{"issue":"1","key":"11108_CR7","volume":"23","author":"J Chen","year":"2024","unstructured":"Chen J, Lau G. HBV \u201cViral Elimination\u201d in the Asia-Pacific region: current status and challenges. Clin Liver Dis (Hoboken). 2024;23(1): e0132","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"7","key":"11108_CR8","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1053\/gast.2001.24839","volume":"120","author":"AS Lok","year":"2001","unstructured":"Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000--summary of a workshop. Gastroenterology. 2001;120(7):1828\u20131853","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"11108_CR9","first-page":"S3","volume":"39","author":"R de Franchis","year":"2003","unstructured":"de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, et al. EASL International on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Switzerland Consensus statement (long version). J Hepatol. 2003;39(Suppl 1):S3\u2013S25","journal-title":"J Hepatol"},{"issue":"3","key":"11108_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","volume":"2","author":"YF Liaw","year":"2008","unstructured":"Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2(3):263\u201383","journal-title":"Hepatol Int"},{"issue":"3","key":"11108_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"YF Liaw","year":"2012","unstructured":"Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6(3):531\u201361","journal-title":"Hepatol Int"},{"issue":"1","key":"11108_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"S Sarin","year":"2016","unstructured":"Sarin S, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1\u201398","journal-title":"Hepatol Int"},{"issue":"3","key":"11108_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1046\/j.1440-1746.2003.03037.x","volume":"18","author":"YF Liaw","year":"2003","unstructured":"Liaw YF, Leung N, Guan R, Lau GK, Merican I, Asian-Pacific Consensus Working Parties on Hepatitis B. Asian-Pacific consensus statement on the management of chronic Hepatitis B: an update. J Gastroenterol Hepatol. 2003;18(3):239\u2013245","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"11108_CR14","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1478-3231.2005.01134.x","volume":"25","author":"YF Liaw","year":"2005","unstructured":"Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Gane E Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 2005;25(3):472\u201389","journal-title":"Liver Int"},{"issue":"15","key":"11108_CR15","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521\u201331","journal-title":"N Engl J Med"},{"issue":"1","key":"11108_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1440-1746.1999.01812.x","volume":"14","author":"G Lau","year":"1999","unstructured":"Lau G, Carman W, Locarnini S, Okuda K, Lu ZM, Williams R. Lam S Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective. J Gastroenterol Hepatol. 1999;14(1):3\u201312","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"11108_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/liv.13309","volume":"37","author":"GF Chen","year":"2017","unstructured":"Chen GF, Wang C, Lau G. Treatment of chronic hepatitis B infection-2017. Liver Int. 2017;37(Suppl 1):59\u201366","journal-title":"Liver Int"},{"key":"11108_CR18","volume":"8","author":"L Roade","year":"2021","unstructured":"Roade L, Riveiro-Barciela M, Esteban R, Buti M. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis. 2021;8: 2049936120985954","journal-title":"Ther Adv Infect Dis"},{"issue":"4","key":"11108_CR19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41575-022-00724-5","volume":"20","author":"SG Lim","year":"2023","unstructured":"Lim SG, Baumert TF, Boni C, Gane E, Levrero M, Lok AS, et al. The scientific basis of combination therapy for chronic hepatitis B functional cure. Nat Rev Gastroenterol Hepatol. 2023;20(4):238\u201353","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"11108_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jhep.2025.03.024","volume":"83","author":"L Sandmann","year":"2025","unstructured":"Sandmann L. Toward functional cure of hepatitis B: Is combination therapy the key? J Hepatol. 2025;83(1):271\u2013272","journal-title":"J Hepatol"},{"issue":"2","key":"11108_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s12072-024-10774-3","volume":"19","author":"M Eslam","year":"2025","unstructured":"Eslam M, Fan JG, Yu ML, Wong VW, Cua IH, Liu CJ, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2025;19(2):261\u2013301","journal-title":"Hepatol Int"},{"issue":"5","key":"11108_CR22","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/apt.17120","volume":"56","author":"GL Wong","year":"2022","unstructured":"Wong GL, Hui VW, Yip TC, Liang LY, Zhang X, Tse YK, et al. Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma. Aliment Pharmacol Ther. 2022;56(5):869\u201377","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"11108_CR23","first-page":"283","volume":"3","author":"GK Lau","year":"1997","unstructured":"Lau GK, Lai CL, Wu PC. The natural history of chronic hepatitis B infection. Hong Kong Med J. 1997;3(3):283\u2013288","journal-title":"Hong Kong Med J"},{"issue":"10381","key":"11108_CR24","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","volume":"401","author":"WJ Jeng","year":"2023","unstructured":"Jeng WJ, Papatheodoridis GV, Lok ASF. Hepatitis B. Lancet. 2023;401(10381):1039\u20131052","journal-title":"Lancet"},{"issue":"27","key":"11108_CR25","first-page":"369","volume":"92","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Hepatitis B vaccines: WHO position paper - July 2017. Wkly Epidemiol Rec. 2017;92(27):369\u2013392","journal-title":"Wkly Epidemiol Rec"},{"issue":"4","key":"11108_CR26","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.vaccine.2012.10.101","volume":"31","author":"D FitzSimons","year":"2013","unstructured":"FitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Vaccine. 2013;31(4):584\u2013590 (Milan, Italy, 17-18 November 2011.)","journal-title":"Vaccine"},{"issue":"31","key":"11108_CR27","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.3748\/wjg.v28.i31.4249","volume":"28","author":"FA Di Lello","year":"2022","unstructured":"Di Lello FA, Martinez AP, Flichman DM. Insights into induction of the immune response by the hepatitis B vaccine. World J Gastroenterol. 2022;28(31):4249\u20134262","journal-title":"World J Gastroenterol"},{"issue":"9","key":"11108_CR28","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1086\/606119","volume":"200","author":"BJ McMahon","year":"2009","unstructured":"McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200(9):1390\u20136","journal-title":"J Infect Dis"},{"issue":"7","key":"11108_CR29","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/pathogens13070554","volume":"13","author":"N Bello","year":"2024","unstructured":"Bello N, Hudu SA, Alshrari AS, Imam MU, Jimoh AO. Overview of Hepatitis B vaccine non-response and associated B cell amnesia: a scoping review. Pathogens. 2024;13(7):554","journal-title":"Pathogens"},{"issue":"1","key":"11108_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2025.2541873","volume":"47","author":"W Chancharoenthana","year":"2025","unstructured":"Chancharoenthana W, Traitanon O, Leelahavanichkul A, Ronco C. Optimizing hepatitis B vaccination in chronic kidney disease: a comprehensive scoping review of strategies across CKD stages, dialysis, and transplant populations. Ren Fail. 2025;47(1): 2541873","journal-title":"Ren Fail"},{"issue":"6","key":"11108_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2016.1277844","volume":"13","author":"FX Catherine","year":"2017","unstructured":"Catherine FX, Piroth L. Hepatitis B virus vaccination in HIV-infected people: a review. Hum Vaccin Immunother. 2017;13(6):1\u201310","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"11108_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1128\/CMR.13.3.385","volume":"13","author":"EM Beltrami","year":"2000","unstructured":"Beltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and management of blood-borne infections in health care workers. Clin Microbiol Rev. 2000;13(3):385\u2013407","journal-title":"Clin Microbiol Rev"},{"issue":"39","key":"11108_CR33","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.15585\/mmwr.mm6439a6","volume":"64","author":"S Schillie","year":"2015","unstructured":"Schillie S, Murphy TV, Fenlon N, Ko S, Ward JW. Update: shortened interval for postvaccination serologic testing of infants born to Hepatitis B-infected mothers. MMWR Morb Mortal Wkly Rep. 2015;64(39):1118\u20131120","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"11108_CR34","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/j.cgh.2018.10.007","volume":"17","author":"J Hou","year":"2019","unstructured":"Hou J, Cui F, Ding Y, Dou X, Duan Z, Han G, et al. Management algorithm for interrupting mother-to-child transmission of hepatitis B Virus. Clin Gastroenterol Hepatol. 2019;17(10):1929\u201336.e1","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1(Suppl 1","key":"11108_CR35","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1093\/jpids\/piu064","volume":"3","author":"NP Nelson","year":"2014","unstructured":"Nelson NP, Jamieson DJ, Murphy TV. Prevention of perinatal Hepatitis B virus transmission. J Pediatr Infect Dis Soc. 2014;3(Suppl 1(Suppl 1)):S7\u2013S12","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"1","key":"11108_CR36","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/s12879-016-1754-1","volume":"16","author":"L Zhang","year":"2016","unstructured":"Zhang L, Gui XE, Wang B, Fan JY, Cao Q, Mullane K, et al. Serological pogvvsitive markers of hepatitis B virus in femoral venous blood or umbilical cord blood should not be evidence of in-utero infection among neonates. BMC Infect Dis. 2016;16(1):408","journal-title":"BMC Infect Dis"},{"issue":"48 Pt B","key":"11108_CR37","doi-asserted-by":"publisher","first-page":"6627","DOI":"10.1016\/j.vaccine.2017.10.032","volume":"35","author":"Y Lu","year":"2017","unstructured":"Lu Y, Zhu FC, Liu JX, Zhai XJ, Chang ZJ, Yan L, et al. The maternal viral threshold for antiviral prophylaxis of perinatal hepatitis B virus transmission in settings with limited resources: A large prospective cohort study in China. Vaccine. 2017;35(48 Pt B):6627\u201333","journal-title":"Vaccine"},{"issue":"3","key":"11108_CR38","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.vaccine.2009.10.068","volume":"28","author":"J Poorolajal","year":"2010","unstructured":"Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine. 2010;28(3):623\u2013631","journal-title":"Vaccine"},{"issue":"2","key":"11108_CR39","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/cid\/ciab405","volume":"74","author":"M Toy","year":"2022","unstructured":"Toy M, Hutton D, Harris AM, Nelson N, Salomon JA, So S. Cost-effectiveness of 1-time universal screening for chronic hepatitis B infection in adults in the United States. Clin Infect Dis. 2022;74(2):210\u2013217","journal-title":"Clin Infect Dis"},{"issue":"5","key":"11108_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.70027","volume":"32","author":"NS Wong","year":"2025","unstructured":"Wong NS, Chan DP, Wong GL, Lee SS. Cost-effectiveness of universal screen-and-treat strategies for reducing morbidity and mortality of chronic Hepatitis B in a high-endemicity city. J Viral Hepat. 2025;32(5): e70027","journal-title":"J Viral Hepat"},{"issue":"11","key":"11108_CR41","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/cid\/cir199","volume":"52","author":"MH Eckman","year":"2011","unstructured":"Eckman MH, Kaiser TE, Sherman KE. The cost-effectiveness of screening for chronic Hepatitis B infection in the United States. Clin Infect Dis. 2011;52(11):1294\u20131306","journal-title":"Clin Infect Dis"},{"issue":"1","key":"11108_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7201a1","volume":"72","author":"EE Conners","year":"2023","unstructured":"Conners EE, Panagiotakopoulos L, Hofmeister MG, Spradling PR, Hagan LM, Harris AM, et al. Screening and testing for Hepatitis B virus infection CDC recommendations - United States. MMWR Recomm Rep. 2023;72(1):1\u201325","journal-title":"MMWR Recomm Rep"},{"key":"11108_CR43","unstructured":"World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva, 2024."},{"issue":"5","key":"11108_CR44","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","volume":"15","author":"G Lau","year":"2021","unstructured":"Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int. 2021;15(5):1031\u201348","journal-title":"Hepatol Int"},{"issue":"6","key":"11108_CR45","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s12072-019-09988-7","volume":"13","author":"T Kanda","year":"2019","unstructured":"Kanda T, Lau GK, Wei L, Moriyama M, Yu ML, Chuang WL, et al. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatol Int. 2019;13(6):649\u201361","journal-title":"Hepatol Int"},{"issue":"4","key":"11108_CR46","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/cid\/ciae288","volume":"79","author":"CQ Pan","year":"2024","unstructured":"Pan CQ, Zhu L, Yu AS, Zhao Y, Zhu B, Dai E. Tenofovir alafenamide versus tenofovir disoproxil fumarate for preventing vertical transmission in chronic Hepatitis B mothers: A systematic review and meta-analysis. Clin Infect Dis. 2024;79(4):953\u2013964","journal-title":"Clin Infect Dis"},{"issue":"2","key":"11108_CR47","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","volume":"66","author":"M Cornberg","year":"2017","unstructured":"Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HLA, Chan HL. The role of quantitative Hepatitis B surface antigen revisited. J Hepatol. 2017;66(2):398\u2013411","journal-title":"J Hepatol"},{"issue":"11","key":"11108_CR48","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41575-022-00649-z","volume":"19","author":"A Kramvis","year":"2022","unstructured":"Kramvis A, Chang KM, Dandri M, Farci P, Glebe D, Hu J, et al. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol. 2022;19(11):727\u201345","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5 Suppl","key":"11108_CR49","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1002\/hep.22930","volume":"49","author":"H Mani","year":"2009","unstructured":"Mani H, Kleiner DE. Liver biopsy findings in chronic Hepatitis B. Hepatology. 2009;49(5 Suppl):S61-71","journal-title":"Hepatology"},{"issue":"23","key":"11108_CR50","first-page":"2296","volume":"377","author":"EB Tapper","year":"2017","unstructured":"Tapper EB, Lok ASF. Use of liver imaging and biopsy in clinical practice. N Engl J Med. 2017;377(23):2296\u20132297","journal-title":"N Engl J Med"},{"issue":"4","key":"11108_CR51","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S2468-1253(24)00437-0","volume":"10","author":"A Liguori","year":"2025","unstructured":"Liguori A, Zoncape M, Casazza G, Easterbrook P, Tsochatzis EA. Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025;10(4):332\u2013349","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl","key":"11108_CR52","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.3350\/cmh.2024.0371","volume":"30","author":"MN Kim","year":"2024","unstructured":"Kim MN, An J, Kim EH, Kim HY, Lee HA, Yu JH, et al. Vibration-controlled transient elastography for significant fibrosis in treatment-naive chronic hepatitis B patients: A systematic review and meta-analysis. Clin Mol Hepatol. 2024;30(Suppl):S106\u2013S16","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"11108_CR53","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/hep.30833","volume":"71","author":"GL Wong","year":"2020","unstructured":"Wong GL, Wong VW, Yuen BW, Tse YK, Luk HW, Yip TC, et al. An aging population of chronic hepatitis B with increasing comorbidities: a territory-wide study from 2000 to 2017. Hepatology. 2020;71(2):444\u201355","journal-title":"Hepatology"},{"issue":"23","key":"11108_CR54","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.21037\/atm-21-3052","volume":"9","author":"D Jiang","year":"2021","unstructured":"Jiang D, Chen C, Liu X, Huang C, Yan D, Zhang X, et al. Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta-analysis. Ann Transl Med. 2021;9(23):1718","journal-title":"Ann Transl Med"},{"issue":"1","key":"11108_CR55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jhepr.2019.02.002","volume":"1","author":"N Peleg","year":"2019","unstructured":"Peleg N, Issachar A, Arbib OS, Cohen-Naftaly M, Braun M, Leshno M, et al. Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load. JHEP Rep. 2019;1(1):9\u201316","journal-title":"JHEP Rep"},{"issue":"1","key":"11108_CR56","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/gut.2008.157735","volume":"58","author":"GL Wong","year":"2009","unstructured":"Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut. 2009;58(1):111\u20137","journal-title":"Gut"},{"issue":"2","key":"11108_CR57","doi-asserted-by":"publisher","first-page":"101589","DOI":"10.1016\/j.aohep.2024.101589","volume":"30","author":"S Hong","year":"2024","unstructured":"Hong S, Hao Y, Sun L, Li P, Yang J, Zhang F, et al. Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease. Ann Hepatol. 2024;30(2):101589","journal-title":"Ann Hepatol"},{"issue":"9865","key":"11108_CR58","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468\u201375","journal-title":"Lancet"},{"issue":"10","key":"11108_CR59","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/jvh.13872","volume":"30","author":"R Zhou","year":"2023","unstructured":"Zhou R, Yang L, Zhang B, Gu Y, Kong T, Zhang W, et al. Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta-analysis. J Viral Hepat. 2023;30(10):793\u2013802","journal-title":"J Viral Hepat"},{"key":"11108_CR60","doi-asserted-by":"publisher","first-page":"155819","DOI":"10.1016\/j.metabol.2024.155819","volume":"154","author":"E Han","year":"2024","unstructured":"Han E, Lee BW, Kang ES, Cha BS, Ahn SH, Lee YH, et al. Corrigendum to \u201cMortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study\u201d [Metabolism, Volume 152, March 2024, 155789]. Metabolism. 2024;154:155819","journal-title":"Metabolism"},{"key":"11108_CR61","doi-asserted-by":"publisher","first-page":"155789","DOI":"10.1016\/j.metabol.2024.155789","volume":"152","author":"E Han","year":"2024","unstructured":"Han E, Lee BW, Kang ES, Cha BS, Ahn SH, Lee YH, et al. Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study. Metabolism. 2024;152:155789","journal-title":"Metabolism"},{"issue":"1","key":"11108_CR62","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","volume":"22","author":"QM Anstee","year":"2024","unstructured":"Anstee QM, Neuschwander-Tetri BA, Wong VW, Abdelmalek MF, Rodriguez-Araujo G, Landgren H, et al. Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study. Clin Gastroenterol Hepatol. 2024;22(1):124\u201334 e1","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"11108_CR63","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497\u2013509","journal-title":"N Engl J Med"},{"issue":"1","key":"11108_CR64","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","volume":"73","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 2020;73(1):26\u201339","journal-title":"J Hepatol"},{"issue":"21","key":"11108_CR65","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399","journal-title":"N Engl J Med"},{"issue":"6","key":"11108_CR66","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.jhep.2024.11.018","volume":"82","author":"JC Lai","year":"2025","unstructured":"Lai JC, Wong GL, Tse YK, Hui VW, Lai MS, Chan HL, et al. Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: A systematic review and meta-analysis. J Hepatol. 2025;82(6):992\u20131003","journal-title":"J Hepatol"},{"issue":"4","key":"11108_CR67","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2468-1253(24)00431-X","volume":"10","author":"YS Lim","year":"2025","unstructured":"Lim YS, Yu ML, Choi J, Chen CY, Choi WM, Kang W, et al. Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial. Lancet Gastroenterol Hepatol. 2025;10(4):295\u2013305","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"11108_CR68","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1097\/HEP.0000000000000459","volume":"78","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Tran A, Yeh ML, Yasuda S, Tsai PC, Huang CF, et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase. Hepatology. 2023;78(5):1558\u201368","journal-title":"Hepatology"},{"issue":"5","key":"11108_CR69","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/liv.15541","volume":"43","author":"KW Lin","year":"2023","unstructured":"Lin KW, Kumar R, Shen F, Chan HL, Wong GL, Kumar R, et al. The utility of non-invasive tests to assess advanced fibrosis in Asian subjects with chronic hepatitis B and concomitant hepatic steatosis. Liver Int. 2023;43(5):1008\u201314","journal-title":"Liver Int"},{"key":"11108_CR70","doi-asserted-by":"publisher","first-page":"6722810","DOI":"10.1155\/grp\/6722810","volume":"2024","author":"Y Liu","year":"2024","unstructured":"Liu Y, Huang Z, Lan X, Jia M, Zheng X, Hu M, et al. Diagnostic efficacy of vibration-controlled transient elastography in patients with metabolic dysfunction-associated liver disease and chronic hepatitis B. Gastroenterol Res Pract. 2024;2024:6722810","journal-title":"Gastroenterol Res Pract"},{"issue":"8","key":"11108_CR71","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","volume":"15","author":"VW Wong","year":"2018","unstructured":"Wong VW, Adams LA, de Ledinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461\u2013478","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"11108_CR72","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jhep.2015.11.012","volume":"64","author":"WR Kim","year":"2016","unstructured":"Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64(4):773\u201380","journal-title":"J Hepatol"},{"issue":"11","key":"11108_CR73","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1136\/gutjnl-2018-317334","volume":"68","author":"VW Wong","year":"2019","unstructured":"Wong VW, Irles M, Wong GL, Shili S, Chan AW, Merrouche W, et al. Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. Gut. 2019;68(11):2057\u201364","journal-title":"Gut"},{"key":"11108_CR74","doi-asserted-by":"publisher","first-page":"102419","DOI":"10.1016\/j.eclinm.2023.102419","volume":"68","author":"F Rui","year":"2024","unstructured":"Rui F, Yeo YH, Xu L, Zheng Q, Xu X, Ni W, et al. Development of a machine learning-based model to predict hepatic inflammation in chronic hepatitis B patients with concurrent hepatic steatosis: a cohort study. EClinicalMedicine. 2024;68:102419","journal-title":"EClinicalMedicine"},{"issue":"2","key":"11108_CR75","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1586\/17474124.2015.960398","volume":"9","author":"TH Su","year":"2015","unstructured":"Su TH, Kao JH. Improving clinical outcomes of chronic hepatitis B virus infection. Expert Rev Gastroenterol Hepatol. 2015;9(2):141\u2013154","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"11108_CR76","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hep.28280","volume":"63","author":"AS Lok","year":"2016","unstructured":"Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. 2016;63(1):284\u2013306","journal-title":"Hepatology"},{"issue":"3","key":"11108_CR77","doi-asserted-by":"publisher","first-page":"406","DOI":"10.14309\/ajg.0000000000000490","volume":"115","author":"J Choi","year":"2020","unstructured":"Choi J, Kim GA, Han S, Lim YS. Earlier alanine aminotransferase normalization during antiviral treatment is independently associated with lower risk of hepatocellular carcinoma in chronic hepatitis B. Am J Gastroenterol. 2020;115(3):406\u2013414","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"11108_CR78","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2018.05.009","volume":"69","author":"GL Wong","year":"2018","unstructured":"Wong GL, Chan HL, Tse YK, Yip TC, Lam KL, Lui GC, et al. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. J Hepatol. 2018;69(4):793\u2013802","journal-title":"J Hepatol"},{"issue":"1","key":"11108_CR79","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jhep.2006.08.021","volume":"46","author":"SM Lin","year":"2007","unstructured":"Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007;46(1):45\u201352","journal-title":"J Hepatol"},{"issue":"22","key":"11108_CR80","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1056\/NEJM199605303342202","volume":"334","author":"C Niederau","year":"1996","unstructured":"Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334(22):1422\u20137","journal-title":"N Engl J Med"},{"issue":"1","key":"11108_CR81","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su JU, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65\u201373","journal-title":"JAMA"},{"issue":"5","key":"11108_CR82","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","volume":"142","author":"TC Tseng","year":"2012","unstructured":"Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142(5):1140\u20139 e3 (quiz e13-4)","journal-title":"Gastroenterology"},{"issue":"4","key":"11108_CR83","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000084","volume":"7","author":"WJ Jeng","year":"2023","unstructured":"Jeng WJ, Lok ASF. What will it take to cure hepatitis B? Hepatol Commun. 2023;7(4): e0084","journal-title":"Hepatol Commun"},{"issue":"4","key":"11108_CR84","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s12072-025-10823-5","volume":"19","author":"J Chen","year":"2025","unstructured":"Chen J, Ji D, Jia J, Zhuang H, Zhang X, Wang FS, et al. Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis. Hepatol Int. 2025;19(4):773\u201395","journal-title":"Hepatol Int"},{"issue":"3","key":"11108_CR85","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","volume":"156","author":"YH Yeo","year":"2019","unstructured":"Yeo YH, Ho HJ, Yang HI, Tseng TC, Hosaka T, Trinh HN, et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology. 2019;156(3):635\u201346.e9","journal-title":"Gastroenterology"},{"issue":"11","key":"11108_CR86","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1136\/gutjnl-2025-334911","volume":"74","author":"TC Tseng","year":"2025","unstructured":"Tseng TC, Huang SC, Pan MH, Liu CJ, Chen CJ, Yang WT, et al. Hepatitis B surface antigen level identifies patients with inactive chronic hepatitis B from Asia with HCC risk below surveillance threshold. Gut. 2025;74(11):1896\u2013904","journal-title":"Gut"},{"issue":"12","key":"11108_CR87","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"351","author":"P Marcellin","year":"2004","unstructured":"Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351(12):1206\u201317","journal-title":"N Engl J Med"},{"issue":"26","key":"11108_CR88","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa043470","volume":"352","author":"GK Lau","year":"2005","unstructured":"Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682\u201395","journal-title":"N Engl J Med"},{"issue":"10","key":"11108_CR89","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT, Gish RG, De Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001\u201310","journal-title":"N Engl J Med"},{"issue":"10","key":"11108_CR90","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa051287","volume":"354","author":"CL Lai","year":"2006","unstructured":"Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011\u201320","journal-title":"N Engl J Med"},{"issue":"5","key":"11108_CR91","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/hep.26301","volume":"58","author":"GL Wong","year":"2013","unstructured":"Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58(5):1537\u201347","journal-title":"Hepatology"},{"issue":"5","key":"11108_CR92","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/jgh.12476","volume":"29","author":"WK Seto","year":"2014","unstructured":"Seto WK, Lam YF, Fung J, Wong DK, Huang FY, Hung IF, et al. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. J Gastroenterol Hepatol. 2014;29(5):1028\u201334","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"11108_CR93","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/gutjnl-2014-307023","volume":"64","author":"P Arends","year":"2015","unstructured":"Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015;64(8):1289\u201395","journal-title":"Gut"},{"issue":"3","key":"11108_CR94","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196\u2013206","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"11108_CR95","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HL Chan","year":"2016","unstructured":"Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185\u201395","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"11108_CR96","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/liv.13253","volume":"36","author":"TH Su","year":"2016","unstructured":"Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36(12):1755\u201364","journal-title":"Liver Int"},{"issue":"4","key":"11108_CR97","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672\u201381","journal-title":"J Hepatol"},{"issue":"9","key":"11108_CR98","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/apt.15499","volume":"50","author":"K Liu","year":"2019","unstructured":"Liu K, Choi J, Le A, Yip TC, Wong VW, Chan SL, et al. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. Aliment Pharmacol Ther. 2019;50(9):1037\u201348","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"11108_CR99","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1111\/liv.14155","volume":"39","author":"P Marcellin","year":"2019","unstructured":"Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, et al. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver Int. 2019;39(10):1868\u201375","journal-title":"Liver Int"},{"issue":"11\u201312","key":"11108_CR100","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/apt.18278","volume":"60","author":"M Buti","year":"2024","unstructured":"Buti M, Lim YS, Chan HL, Agarwal K, Marcellin P, Brunetto MR, et al. Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials. Aliment Pharmacol Ther. 2024;60(11\u201312):1573\u201386","journal-title":"Aliment Pharmacol Ther"},{"issue":"44","key":"11108_CR101","doi-asserted-by":"publisher","first-page":"5907","DOI":"10.3748\/wjg.v29.i44.5907","volume":"29","author":"WT Peng","year":"2023","unstructured":"Peng WT, Jiang C, Yang FL, Zhou NQ, Chen KY, Liu JQ, et al. Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study. World J Gastroenterol. 2023;29(44):5907\u201318","journal-title":"World J Gastroenterol"},{"key":"11108_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1545108","volume":"16","author":"X Qiu","year":"2025","unstructured":"Qiu X, Yin Y, Zhang S, Liu W. Effectiveness and safety of tenofovir amibufenamide and tenofovir alafenamide in treating elderly patients diagnosed with decompensated hepatitis B cirrhosis: a retrospective cohort study. Front Pharmacol. 2025;16: 1545108","journal-title":"Front Pharmacol"},{"key":"11108_CR103","doi-asserted-by":"publisher","first-page":"105782","DOI":"10.1016\/j.antiviral.2023.105782","volume":"221","author":"Q Zhao","year":"2024","unstructured":"Zhao Q, Liu H, Tang L, Wang F, Tolufashe G, Chang J, et al. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy. Antiviral Res. 2024;221:105782","journal-title":"Antiviral Res"},{"issue":"15","key":"11108_CR104","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2217\/cer-2020-0068","volume":"9","author":"U Sbarigia","year":"2020","unstructured":"Sbarigia U, Vincken T, Wigfield P, Hashim M, Heeg B, Postma M. A comparative network meta-analysis of standard of care treatments in treatment-naive chronic hepatitis B patients. J Comp Eff Res. 2020;9(15):1051\u20131065","journal-title":"J Comp Eff Res"},{"key":"11108_CR105","doi-asserted-by":"publisher","first-page":"779347","DOI":"10.3389\/fimmu.2021.779347","volume":"12","author":"A Song","year":"2021","unstructured":"Song A, Lin X, Lu J, Ren S, Cao Z, Zheng S, et al. Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis. Front Immunol. 2021;12:779347","journal-title":"Front Immunol"},{"issue":"6","key":"11108_CR106","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s12072-020-10099-x","volume":"14","author":"J Liu","year":"2020","unstructured":"Liu J, Wang T, Zhang W, Cheng Y, He Q, Wang FS. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic Hepatitis B: a systematic review and meta-analysis. Hepatol Int. 2020;14(6):958\u2013972","journal-title":"Hepatol Int"},{"issue":"1","key":"11108_CR107","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","volume":"77","author":"D Huang","year":"2022","unstructured":"Huang D, Wu D, Wang P, Wang Y, Yuan W, Hu D, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol. 2022;77(1):42\u201354","journal-title":"J Hepatol"},{"issue":"7","key":"11108_CR108","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/MCG.0000000000001276","volume":"54","author":"RJ Wong","year":"2020","unstructured":"Wong RJ, Khalili M. A patient-centered Hepatitis B virus (HBV) educational intervention improves HBV care among underserved safety-net populations. J Clin Gastroenterol. 2020;54(7):642\u2013647","journal-title":"J Clin Gastroenterol"},{"issue":"10","key":"11108_CR109","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/hep4.1247","volume":"2","author":"N Ford","year":"2018","unstructured":"Ford N, Scourse R, Lemoine M, Hutin Y, Bulterys M, Shubber Z, et al. Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis. Hepatol Commun. 2018;2(10):1160\u20137","journal-title":"Hepatol Commun"},{"issue":"3","key":"11108_CR110","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1365-2893.2011.01494.x","volume":"19","author":"W Chotiyaputta","year":"2012","unstructured":"Chotiyaputta W, Hongthanakorn C, Oberhelman K, Fontana RJ, Licari T, Lok AS. Adherence to nucleos(t)ide analogues for chronic Hepatitis B in clinical practice and correlation with virological breakthroughs. J Viral Hepat. 2012;19(3):205\u2013212","journal-title":"J Viral Hepat"},{"issue":"7","key":"11108_CR111","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/tmi.14133","volume":"30","author":"L Lutfian","year":"2025","unstructured":"Lutfian L, Wardika IJ, Mukminin MA, Zamroni AH, Rizanti AP, Chandra IN, et al. Effectiveness of health education in improving treatment adherence among patients with chronic communicable diseases: A systematic review and meta-analysis. Trop Med Int Health. 2025;30(7):598\u2013612","journal-title":"Trop Med Int Health"},{"key":"11108_CR112","unstructured":"U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. Dec, 11 ed; 2023."},{"key":"11108_CR113","unstructured":"Two research projects seek to improve immunization practices. Bull Pan Am Health Organ 1992; 26(1): 96-7"},{"issue":"5","key":"11108_CR114","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/1097-0142(19860901)58:5<1055::AID-CNCR2820580513>3.0.CO;2-#","volume":"58","author":"F Imazeki","year":"1986","unstructured":"Imazeki F, Omata M, Yokosuka O, Okuda K. Integration of Hepatitis B virus DNA in hepatocellular carcinoma. Cancer. 1986;58(5):1055\u20131060","journal-title":"Cancer"},{"issue":"10","key":"11108_CR115","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.cgh.2016.01.019","volume":"14","author":"WP Brouwer","year":"2016","unstructured":"Brouwer WP, Chan HL, Brunetto MR, Martinot-Peignoux M, Arends P, Cornberg M, et al. Repeated measurements of hepatitis B Surface antigen identify carriers of inactive HBV During Long-term Follow-up. Clin Gastroenterol Hepatol. 2016;14(10):1481\u20139 e5","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"11108_CR116","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/hep.28552","volume":"64","author":"J Liu","year":"2016","unstructured":"Liu J, Yang HI, Lee MH, Jen CL, Batrla-Utermann R, Lu SN, et al. Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression. Hepatology. 2016;64(2):381\u20139","journal-title":"Hepatology"},{"issue":"2","key":"11108_CR117","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1053\/j.gastro.2011.04.046","volume":"141","author":"TC Tseng","year":"2011","unstructured":"Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology. 2011;141(2):517\u201325","journal-title":"Gastroenterology"},{"issue":"3","key":"11108_CR118","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","volume":"130","author":"UH Iloeje","year":"2006","unstructured":"Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678\u201386","journal-title":"Gastroenterology"},{"issue":"3","key":"11108_CR119","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","volume":"162","author":"G Hirode","year":"2022","unstructured":"Hirode G, Choi HS, Chen CH, Su TH, Seto WK, Van Hees S, et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Gastroenterology. 2022;162(3):757\u201371.e4","journal-title":"Gastroenterology"},{"issue":"10","key":"11108_CR120","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/hep4.1708","volume":"5","author":"F van Bommel","year":"2021","unstructured":"van Bommel F, Berg T. Risks and benefits of discontinuation of nucleos(t)ide analogue treatment: a treatment concept for patients with HBeAg-negative chronic Hepatitis B. Hepatol Commun. 2021;5(10):1632\u20131648","journal-title":"Hepatol Commun"},{"issue":"2","key":"11108_CR121","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jhep.2024.07.019","volume":"82","author":"F Li","year":"2025","unstructured":"Li F, Qu L, Liu Y, Wu X, Qi X, Wang J, et al. PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial. J Hepatol. 2025;82(2):211\u201321","journal-title":"J Hepatol"},{"issue":"5","key":"11108_CR122","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jhep.2023.06.002","volume":"79","author":"MG Ghany","year":"2023","unstructured":"Ghany MG, Buti M, Lampertico P, Lee HM, Faculty A-EH-HTEC. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference. J Hepatol. 2023;79(5):1254\u20131269","journal-title":"J Hepatol"},{"key":"11108_CR123","first-page":"100738","volume":"35","author":"S Zhang","year":"2023","unstructured":"Zhang S, Wang C, Liu B, Lu QB, Shang J, Zhou Y, et al. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation. Lancet Reg Health West Pac. 2023;35:100738","journal-title":"Lancet Reg Health West Pac"},{"issue":"2","key":"11108_CR124","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000299","volume":"12","author":"H Lee","year":"2021","unstructured":"Lee H, Kim BK, Jang S, Ahn SH. Cost-effectiveness analysis of antiviral therapy for untreated minimally active chronic Hepatitis B to prevent liver disease progression. Clin Transl Gastroenterol. 2021;12(2): e00299","journal-title":"Clin Transl Gastroenterol"},{"issue":"9","key":"11108_CR125","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/jvh.13843","volume":"30","author":"D Razavi-Shearer","year":"2023","unstructured":"Razavi-Shearer D, Estes C, Gamkrelidze I, Razavi H. Cost-effectiveness of treating all Hepatitis B-positive individuals in the United States. J Viral Hepat. 2023;30(9):718\u2013726","journal-title":"J Viral Hepat"},{"key":"11108_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/v15040997","author":"YS Lim","year":"2023","unstructured":"Lim YS, Kim WR, Dieterich D, Kao JH, Flaherty JF, Yee LJ, et al. Evidence for benefits of early treatment initiation for chronic hepatitis B. Viruses. 2023. https:\/\/doi.org\/10.3390\/v15040997","journal-title":"Viruses"},{"issue":"4","key":"11108_CR127","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jhep.2023.12.001","volume":"80","author":"TC Yip","year":"2024","unstructured":"Yip TC, Lai JC, Yam TF, Tse YK, Hui VW, Lai MS, et al. Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B. J Hepatol. 2024;80(4):553\u201363","journal-title":"J Hepatol"},{"issue":"3","key":"11108_CR128","doi-asserted-by":"publisher","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","volume":"119","author":"HL Chan","year":"2024","unstructured":"Chan HL, Buti M, Lim YS, Agarwal K, Marcellin P, Brunetto M, et al. Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety. Am J Gastroenterol. 2024;119(3):486\u201396","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"11108_CR129","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1186\/s12889-023-17263-6","volume":"24","author":"M Toumi","year":"2024","unstructured":"Toumi M, Wallace J, Cohen C, Marshall C, Kitchen H, Macey J, et al. Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United States. BMC Public Health. 2024;24(1):611","journal-title":"BMC Public Health"},{"issue":"6","key":"11108_CR130","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1007\/s12072-021-10240-4","volume":"15","author":"X Wu","year":"2021","unstructured":"Wu X, Hong J, Zhou J, Sun Y, Li L, Xie W, et al. Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis. Hepatol Int. 2021;15(6):1318\u201327","journal-title":"Hepatol Int"},{"issue":"2","key":"11108_CR131","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12072-021-10153-2","volume":"15","author":"M Duan","year":"2021","unstructured":"Duan M, Chi X, Xiao H, Liu X, Zhuang H. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic Hepatitis B. Hepatol Int. 2021;15(2):318\u2013327","journal-title":"Hepatol Int"},{"issue":"2","key":"11108_CR132","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/apt.15311","volume":"50","author":"GH Choi","year":"2019","unstructured":"Choi GH, Kim GA, Choi J, Han S, Lim YS. High risk of clinical events in untreated HBeAg-negative chronic Hepatitis B patients with high viral load and no significant ALT elevation. Aliment Pharmacol Ther. 2019;50(2):215\u2013226","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"11108_CR133","doi-asserted-by":"publisher","first-page":"972","DOI":"10.14218\/JCTH.2021.00443","volume":"10","author":"Q Sheng","year":"2022","unstructured":"Sheng Q, Wang N, Zhang C, Fan Y, Li Y, Han C, et al. HBeAg-negative patients with chronic hepatitis B virus infection and normal alanine aminotransferase: wait or treat? J Clin Transl Hepatol. 2022;10(5):972\u20138","journal-title":"J Clin Transl Hepatol"},{"issue":"3","key":"11108_CR134","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jhep.2022.03.032","volume":"77","author":"H Yang","year":"2022","unstructured":"Yang H, Bae SH, Nam H, Lee HL, Lee SW, Yoo SH, et al. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Hepatol. 2022;77(3):632\u201341","journal-title":"J Hepatol"},{"key":"11108_CR135","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-336373","author":"J Chen","year":"2025","unstructured":"Chen J, You H, Lau G. Rethinking \u201cinactive chronic Hepatitis B\u201d: should we treat patients with high HBsAg levels? Gut. 2025. https:\/\/doi.org\/10.1136\/gutjnl-2025-336373","journal-title":"Gut"},{"issue":"4","key":"11108_CR136","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","volume":"15","author":"JH Kao","year":"2021","unstructured":"Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, et al. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int. 2021;15(4):833\u2013851","journal-title":"Hepatol Int"},{"issue":"Suppl","key":"11108_CR137","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.3350\/cmh.2024.0780","volume":"31","author":"D Wu","year":"2025","unstructured":"Wu D, Kao JH, Piratvisuth T, Wang X, Kennedy PT, Otsuka M, et al. Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0. Clin Mol Hepatol. 2025;31(Suppl):S134\u2013S64","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"11108_CR138","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1053\/gast.2002.36026","volume":"123","author":"YC Chen","year":"2002","unstructured":"Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic Hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123(4):1084\u20131089","journal-title":"Gastroenterology"},{"issue":"3","key":"11108_CR139","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","volume":"19","author":"RT Anderson","year":"2021","unstructured":"Anderson RT, Choi HS, Lenz O, Peters MG, Janssen HL, Mishra P, et al. Association between seroclearance of Hepatitis B surface antigen and long-term clinical outcomes of patients with chronic Hepatitis B virus infection: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19(3):463\u201372","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"11108_CR140","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/HEP.0000000000000575","volume":"79","author":"WJ Jeng","year":"2024","unstructured":"Jeng WJ, Chien RN, Chen YC, Lin CL, Wu CY, Liu YC, et al. Hepatocellular carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis B patients with cirrhosis. Hepatology. 2024;79(3):690\u2013703","journal-title":"Hepatology"},{"issue":"9","key":"11108_CR141","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/apt.13150","volume":"41","author":"H Chi","year":"2015","unstructured":"Chi H, Hansen BE, Yim C, Arends P, Abu-Amara M, Van Der Eijk AA, et al. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. Aliment Pharmacol Ther. 2015;41(9):867\u201376","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"11108_CR142","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/infdis\/jiy350","volume":"218","author":"C H\u00f6ner zu Siederdissen","year":"2018","unstructured":"H\u00f6ner zu Siederdissen C, Hui AJ, Sukeepaisarnjaroen W, Tangkijvanich P, Su WW, Nieto GE, et al. Contrasting timing of virological relapse after discontinuation of tenofovir or entecavir in Hepatitis B e Antigen-negative patients. J Infect Dis. 2018;218(9):1480\u20134","journal-title":"J Infect Dis"},{"issue":"3","key":"11108_CR143","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jhep.2024.08.015","volume":"82","author":"EJ Dongelmans","year":"2025","unstructured":"Dongelmans EJ, Hirode G, Hansen BE, Chen CH, Su TH, Seto WK, et al. Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study). J Hepatol. 2025;82(3):446\u201355","journal-title":"J Hepatol"},{"issue":"2","key":"11108_CR144","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jhep.2013.04.019","volume":"59","author":"KW Cheung","year":"2013","unstructured":"Cheung KW, Seto MT, Lee CP. Mother-to-infant transmission of Hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol. 2013;59(2):400","journal-title":"J Hepatol"},{"issue":"24","key":"11108_CR145","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","volume":"374","author":"CQ Pan","year":"2016","unstructured":"Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to prevent Hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324\u201334","journal-title":"N Engl J Med"},{"issue":"1","key":"11108_CR146","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/hep.28302","volume":"63","author":"RS Brown Jr","year":"2016","unstructured":"Brown RS Jr, McMahon BJ, Lok AS, Wong JB, Ahmed AT, Mouchli MA, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology. 2016;63(1):319\u201333","journal-title":"Hepatology"},{"issue":"3","key":"11108_CR147","doi-asserted-by":"publisher","first-page":"365.e1","DOI":"10.1016\/j.ajog.2014.09.032","volume":"212","author":"MS Chang","year":"2015","unstructured":"Chang MS, Tuomala R, Rutherford AE, Mutinga ML, Andersson KL, Burman BE, et al. Postpartum care for mothers diagnosed with hepatitis B during pregnancy. Am J Obstet Gynecol. 2015;212(3):365.e1\u20137","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"11108_CR148","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jama.2019.1655","volume":"322","author":"JT Henderson","year":"2019","unstructured":"Henderson JT, Webber EM, Bean SI. Screening for Hepatitis B infection in pregnant women: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2019;322(4):360\u2013362","journal-title":"JAMA"},{"issue":"1","key":"11108_CR149","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.amepre.2023.01.041","volume":"65","author":"TT Pham","year":"2023","unstructured":"Pham TT, Maria N, Cheng V, Nguyen B, Toy M, Hutton D, et al. Gaps in prenatal Hepatitis B screening and management of HBsAg positive pregnant persons in the US, 2015\u20132020. Am J Prev Med. 2023;65(1):52\u20139","journal-title":"Am J Prev Med"},{"issue":"1","key":"11108_CR150","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S1473-3099(20)30586-7","volume":"21","author":"AL Funk","year":"2021","unstructured":"Funk AL, Lu Y, Yoshida K, Zhao T, Boucheron P, van Holten J, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis. 2021;21(1):70\u201384","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"11108_CR151","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s12072-021-10235-1","volume":"15","author":"B Li","year":"2021","unstructured":"Li B, Liu Z, Liu X, Liu D, Duan M, Gu Y, et al. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load. Hepatol Int. 2021;15(5):1103\u20138","journal-title":"Hepatol Int"},{"issue":"9","key":"11108_CR152","doi-asserted-by":"publisher","first-page":"e3324","DOI":"10.1093\/cid\/ciaa1939","volume":"73","author":"QL Zeng","year":"2021","unstructured":"Zeng QL, Yu ZJ, Ji F, Li GM, Zhang GF, Xu JH, et al. Tenofovir alafenamide to prevent perinatal Hepatitis B transmission: a multicenter, prospective. Observational Study Clin Infect Dis. 2021;73(9):e3324\u2013e32","journal-title":"Observational Study. Clin Infect Dis"},{"issue":"5","key":"11108_CR153","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/jama.2024.22952","volume":"333","author":"CQ Pan","year":"2025","unstructured":"Pan CQ, Dai E, Mo Z, Zhang H, Zheng TQ, Wang Y, et al. Tenofovir and Hepatitis B Virus Transmission During Pregnancy: A Randomized Clinical Trial. JAMA. 2025;333(5):390\u20139","journal-title":"JAMA"},{"issue":"3","key":"11108_CR154","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/MCG.0000000000000822","volume":"52","author":"CY Chang","year":"2018","unstructured":"Chang CY, Aziz N, Poongkunran M, Javaid A, Trinh HN, Lau DT, et al. Serum aminotransferase flares in pregnant and postpartum women with current or prior treatment for chronic Hepatitis B. J Clin Gastroenterol. 2018;52(3):255\u201361","journal-title":"J Clin Gastroenterol"},{"issue":"10","key":"11108_CR155","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1111\/apt.12726","volume":"39","author":"V Nguyen","year":"2014","unstructured":"Nguyen V, Tan PK, Greenup AJ, Glass A, Davison S, Samarasinghe D, et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Aliment Pharmacol Ther. 2014;39(10):1225\u201334","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"11108_CR156","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/QAD.0000000000001313","volume":"31","author":"LM Mofenson","year":"2017","unstructured":"Mofenson LM, Baggaley RC, Mameletzis I. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. AIDS. 2017;31(2):213\u2013232","journal-title":"AIDS"},{"issue":"1","key":"11108_CR157","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202\u20139","journal-title":"J Hepatol"},{"issue":"5","key":"11108_CR158","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/hep.32792","volume":"77","author":"X Mao","year":"2023","unstructured":"Mao X, Cheung KS, Peng C, Mak LY, Cheng HM, Fung J, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis. Hepatology. 2023;77(5):1735\u201345","journal-title":"Hepatology"},{"issue":"5","key":"11108_CR159","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s12072-023-10545-6","volume":"17","author":"SC Huang","year":"2023","unstructured":"Huang SC, Su TH, Tseng TC, Chen CL, Hsu SJ, Liao SH, et al. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B. Hepatol Int. 2023;17(5):1139\u201349","journal-title":"Hepatol Int"},{"issue":"3","key":"11108_CR160","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cgh.2023.09.040","volume":"22","author":"SC Huang","year":"2024","unstructured":"Huang SC, Su TH, Tseng TC, Chen CL, Hsu SJ, Liu CH, et al. Metabolic dysfunction-associated steatotic liver disease facilitates Hepatitis B surface antigen seroclearance and seroconversion. Clin Gastroenterol Hepatol. 2024;22(3):581\u201390 e6","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"11108_CR161","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jhep.2024.12.009","volume":"83","author":"SC Huang","year":"2025","unstructured":"Huang SC, Su TH, Tseng TC, Hsu SJ, Hong CM, Lan TY, et al. All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease. J Hepatol. 2025;83(1):43\u201351","journal-title":"J Hepatol"},{"issue":"2","key":"11108_CR162","doi-asserted-by":"publisher","first-page":"401","DOI":"10.14309\/ajg.0000000000002915","volume":"120","author":"SC Huang","year":"2025","unstructured":"Huang SC, Su TH, Tseng TC, Liao SH, Hsu SJ, Hong CM, et al. Pre-existing and new-onset metabolic dysfunctions increase cirrhosis and its complication risks in chronic Hepatitis B. Am J Gastroenterol. 2025;120(2):401\u20139","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"11108_CR163","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1016\/j.cgh.2023.02.004","volume":"21","author":"TC Yip","year":"2023","unstructured":"Yip TC, Wong VW, Lai MS, Lai JC, Tse YK, Liang LY, et al. Diabetes mellitus impacts on the performance of hepatocellular carcinoma risk scores in chronic Hepatitis B patients. Clin Gastroenterol Hepatol. 2023;21(11):2864\u201375.e16","journal-title":"Clin Gastroenterol Hepatol"},{"key":"11108_CR164","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001357","author":"JB Schwimmer","year":"2025","unstructured":"Schwimmer JB, Thai NQ, Noon SL, Ugalde-Nicalo P, Anderson SR, Chun LF, et al. Long-term mortality and extrahepatic outcomes in 1096 children with MASLD: A retrospective cohort study. Hepatology. 2025. https:\/\/doi.org\/10.1097\/hep.0000000000001357","journal-title":"Hepatology"},{"issue":"6","key":"11108_CR165","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1007\/s12072-023-10574-1","volume":"17","author":"J Zeng","year":"2023","unstructured":"Zeng J, Jin Q, Yang J, Yang RX, Zhang RN, Zhao J, et al. Prevalence and incidence of MAFLD and associated anthropometric parameters among prepubertal children of the Shanghai Birth Cohort. Hepatol Int. 2023;17(6):1416\u201328","journal-title":"Hepatol Int"},{"issue":"9","key":"11108_CR166","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1111\/liv.15080","volume":"42","author":"ZY Zou","year":"2022","unstructured":"Zou ZY, Zeng J, Ren TY, Huang LJ, Wang MY, Shi YW, et al. The burden and sexual dimorphism with nonalcoholic fatty liver disease in Asian children: A systematic review and meta-analysis. Liver Int. 2022;42(9):1969\u201380","journal-title":"Liver Int"},{"key":"11108_CR167","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12122903","author":"C Huang","year":"2024","unstructured":"Huang C, Lu Y, Wang Z, Jiang Q, Dong Y, Cao L, et al. Correlation between clinical indicators and liver pathology in children with chronic Hepatitis B. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12122903","journal-title":"Biomedicines"},{"issue":"12","key":"11108_CR168","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1007\/s00535-019-01594-6","volume":"54","author":"L Wang","year":"2019","unstructured":"Wang L, Wang Y, Liu S, Zhai X, Zhou G, Lu F, et al. Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population. J Gastroenterol. 2019;54(12):1096\u2013105","journal-title":"J Gastroenterol"},{"issue":"1","key":"11108_CR169","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s12887-025-05759-6","volume":"25","author":"K Talebi Anaraki","year":"2025","unstructured":"Talebi Anaraki K, Heidari-Beni M, Arefian M, Kelishadi R. Managing pediatric metabolic syndrome: a systematic review of current approaches. BMC Pediatr. 2025;25(1):431","journal-title":"BMC Pediatr"},{"key":"11108_CR170","doi-asserted-by":"publisher","DOI":"10.3390\/nu12092864","author":"CN Katsagoni","year":"2020","unstructured":"Katsagoni CN, Papachristou E, Sidossis A, Sidossis L. Effects of dietary and lifestyle interventions on liver, clinical and metabolic parameters in children and adolescents with Non-Alcoholic Fatty Liver Disease: a systematic review. Nutrients. 2020. https:\/\/doi.org\/10.3390\/nu12092864","journal-title":"Nutrients"},{"issue":"5","key":"11108_CR171","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.hbpd.2021.06.009","volume":"20","author":"XJ Chang","year":"2021","unstructured":"Chang XJ, Shi YW, Wang J, Liu HB, Chen Y, Zhu XN, et al. Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment. Hepatobiliary Pancreat Dis Int. 2021;20(5):416\u201325","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"11108_CR172","unstructured":"UNAIDS. Global HIV & AIDS statistics \u2014 Fact sheet. 2025. https:\/\/www.unaids.org\/en\/resources\/fact-sheet (accessed 24 Oct 2025)."},{"issue":"11","key":"11108_CR173","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/cid\/ciz1170","volume":"71","author":"S Leumi","year":"2020","unstructured":"Leumi S, Bigna JJ, Amougou MA, Ngouo A, Nyaga UF, Noubiap JJ. Global burden of Hepatitis B infection in people living with Human Immunodeficiency Virus: A systematic review and meta-analysis. Clin Infect Dis. 2020;71(11):2799\u20132806","journal-title":"Clin Infect Dis"},{"issue":"12","key":"11108_CR174","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/infdis\/jiaa662","volume":"223","author":"S Yoshikawa","year":"2021","unstructured":"Yoshikawa S, Yoshio S, Yoshida Y, Tsutsui Y, Kawai H, Yamazoe T, et al. Impact of immune reconstitution-induced hepatic flare on Hepatitis B surface antigen loss in Hepatitis B virus\/human immunodeficiency virus-1 coinfected patients. J Infect Dis. 2021;223(12):2080\u20139","journal-title":"J Infect Dis"},{"issue":"3","key":"11108_CR175","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.05125-22","volume":"11","author":"YS Huang","year":"2023","unstructured":"Huang YS, Cheng CY, Sun HY, Cheng SH, Lu PL, Lee CH, et al. Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV\/Hepatitis B Virus-Coinfected Patients. Microbiol Spectr. 2023;11(3): e0512522","journal-title":"Microbiol Spectr"},{"issue":"25","key":"11108_CR176","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1056\/NEJMoa067710","volume":"356","author":"MA McMahon","year":"2007","unstructured":"McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med. 2007;356(25):2614\u201321","journal-title":"N Engl J Med"},{"issue":"9","key":"11108_CR177","doi-asserted-by":"publisher","first-page":"ofac451","DOI":"10.1093\/ofid\/ofac451","volume":"9","author":"M Iannetta","year":"2022","unstructured":"Iannetta M, Crea AM, Di Lorenzo A, Campogiani L, Teti E, Malagnino V, et al. Hepatitis B-Related Hepatic Flare During Immune Reconstitution Syndrome After Antiretroviral Treatment Initiation in an HBV Surface Antigen-Positive Patient With HIV: Viroimmunological and Histological Characterization. Open Forum Infect Dis. 2022;9(9):ofac451","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"11108_CR178","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/jmv.1890180110","volume":"18","author":"M Buti","year":"1986","unstructured":"Buti M, Esteban R, Jardi R, Esteban JI, Guardia J. Serological diagnosis of acute Delta hepatitis. J Med Virol. 1986;18(1):81\u201385","journal-title":"J Med Virol"},{"key":"11108_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104995","volume":"185","author":"A Abdrakhman","year":"2021","unstructured":"Abdrakhman A, Ashimkhanova A, Almawi WY. Effectiveness of pegylated interferon monotherapy in the treatment of chronic Hepatitis D virus infection: A meta-analysis. Antiviral Res. 2021;185: 104995","journal-title":"Antiviral Res"},{"issue":"4","key":"11108_CR180","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jhep.2024.05.001","volume":"81","author":"H Wedemeyer","year":"2024","unstructured":"Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P, et al. Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial. J Hepatol. 2024;81(4):621\u20139","journal-title":"J Hepatol"},{"key":"11108_CR181","unstructured":"Foundation; HB. Drug Profile: Three Hepatitis Delta Therapies That We Hope to See Widely Available Soon. 2023. https:\/\/www.hepb.org\/blog\/drug-profile-three-hepatitis-delta-therapies-hope-see-widely-available-soon\/ (accessed 15 Jan 2026)."},{"issue":"10","key":"11108_CR182","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1097\/TP.0000000000004138","volume":"106","author":"S Martini","year":"2022","unstructured":"Martini S, Tandoi F, Romagnoli R, Rizzetto M. Liver transplantation in Hepatitis B\/Hepatitis D (Delta) virus coinfected recipients. Transplantation. 2022;106(10):1935\u20131939","journal-title":"Transplantation"},{"issue":"9539","key":"11108_CR183","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/S0140-6736(06)69374-4","volume":"368","author":"J Amin","year":"2006","unstructured":"Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of Hepatitis B or Hepatitis C infection: A large community-based linkage study. Lancet. 2006;368(9539):938\u2013945","journal-title":"Lancet"},{"issue":"1","key":"11108_CR184","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/hep.29109","volume":"66","author":"G Chen","year":"2017","unstructured":"Chen G, Wang C, Chen J, Ji D, Wang Y, Wu V, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Hepatology. 2017;66(1):13\u201326","journal-title":"Hepatology"},{"issue":"3","key":"11108_CR185","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","volume":"3","author":"MM M\u00fccke","year":"2018","unstructured":"M\u00fccke MM, Backus LI, Muecke VT, Coppola N, Preda CM, Yeh ML, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(3):172\u201380","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"11108_CR186","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1016\/j.cgh.2021.11.032","volume":"20","author":"PN Cheng","year":"2022","unstructured":"Cheng PN, Liu CJ, Chen CY, Tseng KC, Lo CC, Peng CY, et al. Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV\/HBV Dual Infection: A Randomized Trial. Clin Gastroenterol Hepatol. 2022;20(12):2800\u20138","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"11108_CR187","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jhep.2020.01.027","volume":"73","author":"ML Yeh","year":"2020","unstructured":"Yeh ML, Huang CF, Huang CI, Holmes JA, Hsieh MH, Tsai YS, et al. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV\/HCV co-infection. J Hepatol. 2020;73(1):62\u201371","journal-title":"J Hepatol"},{"key":"11108_CR188","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12121957","author":"JH Oh","year":"2022","unstructured":"Oh JH, Park DA, Ko MJ, Yoo JJ, Yim SY, Ahn JH, et al. Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis. J Pers Med. 2022. https:\/\/doi.org\/10.3390\/jpm12121957","journal-title":"J Pers Med"},{"issue":"2","key":"11108_CR189","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516\u2013537","journal-title":"J Hepatol"},{"issue":"2","key":"11108_CR190","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/HEP.0000000000000570","volume":"79","author":"J Gratac\u00f3s-Gin\u00e8s","year":"2024","unstructured":"Gratac\u00f3s-Gin\u00e8s J, Bruguera P, P\u00e9rez-Guasch M, L\u00f3pez-Lazcano A, Borr\u00e0s R, Hern\u00e1ndez-\u00c9vole H, et al. Medications for alcohol use disorder promote abstinence in alcohol-associated cirrhosis: Results from a systematic review and meta-analysis. Hepatology. 2024;79(2):368\u201379","journal-title":"Hepatology"},{"issue":"8","key":"11108_CR191","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/apt.17665","volume":"58","author":"C Oldroyd","year":"2023","unstructured":"Oldroyd C, Greenham O, Martin G, Allison M, Notley C. Systematic review: interventions for alcohol use disorder in patients with cirrhosis or alcohol-associated hepatitis. Aliment Pharmacol Ther. 2023;58(8):763\u2013773","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"11108_CR192","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/MEG.0000000000002304","volume":"34","author":"LD Tyson","year":"2022","unstructured":"Tyson LD, Cheng A, Kelleher C, Strathie K, Lovendoski J, Habtemariam Z, et al. Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice. Eur J Gastroenterol Hepatol. 2022;34(5):567\u201375","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"11108_CR193","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2021.7683","volume":"326","author":"AK Singal","year":"2021","unstructured":"Singal AK, Mathurin P. Diagnosis and treatment of alcohol-associated liver disease: a review. JAMA. 2021;326(2):165\u2013176","journal-title":"JAMA"},{"issue":"6","key":"11108_CR194","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/hep.27723","volume":"61","author":"JW Jang","year":"2015","unstructured":"Jang JW, Choi JY, Kim YS, Woo HY, Choi SK, Lee CH, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology. 2015;61(6):1809\u201320","journal-title":"Hepatology"},{"issue":"2","key":"11108_CR195","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/apt.12344","volume":"38","author":"AK Singal","year":"2013","unstructured":"Singal AK, Salameh H, Kuo YF, Fontana RJ. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther. 2013;38(2):98\u2013106","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"11108_CR196","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jhep.2009.11.007","volume":"52","author":"JH Shim","year":"2010","unstructured":"Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010;52(2):176\u201382","journal-title":"J Hepatol"},{"issue":"10","key":"11108_CR197","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1365-2893.2012.01600.x","volume":"19","author":"HL Chan","year":"2012","unstructured":"Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat. 2012;19(10):732\u201343","journal-title":"J Viral Hepat"},{"issue":"1","key":"11108_CR198","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/hep.24361","volume":"54","author":"YF Liaw","year":"2011","unstructured":"Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54(1):91\u2013100","journal-title":"Hepatology"},{"key":"11108_CR199","doi-asserted-by":"publisher","first-page":"1529201","DOI":"10.3389\/fmed.2025.1529201","volume":"12","author":"L Huang","year":"2025","unstructured":"Huang L, Feng L, Lu Y, Hu B, Liang H, Ren A, et al. Evaluating the predictive value of clinical models for HBV-related hepatocellular carcinoma: A meta-analysis. Front Med (Lausanne). 2025;12:1529201","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"11108_CR200","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.14309\/ajg.0000000000001865","volume":"117","author":"S Wu","year":"2022","unstructured":"Wu S, Zhou J, Wu X, Sun Y, Wang B, Kong Y, et al. Comparative Performance of 14 HCC Prediction Models in CHB: A Dynamic Validation at Serial On-Treatment Timepoints. Am J Gastroenterol. 2022;117(9):1444\u201353","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"11108_CR201","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-023-02145-5","volume":"20","author":"X Xu","year":"2023","unstructured":"Xu X, Jiang L, Zeng Y, Pan L, Lou Z, Ruan B. HCC prediction models in chronic hepatitis B patients receiving entecavir or tenofovir: a systematic review and meta-analysis. Virol J. 2023;20(1): 180","journal-title":"Virol J"},{"issue":"5","key":"11108_CR202","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jhep.2019.12.005","volume":"72","author":"TC Yip","year":"2020","unstructured":"Yip TC, Wong GL, Wong VW, Tse YK, Liang LY, Hui VW, et al. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. J Hepatol. 2020;72(5):847\u201354","journal-title":"J Hepatol"},{"issue":"2","key":"11108_CR203","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/1751-2980.13172","volume":"24","author":"HY Chon","year":"2023","unstructured":"Chon HY, Lee HA, Park SY, Seo YS, Kim SG, Lee CH, et al. CAGE-B and SAGE-B models better predict the hepatitis B virus-related hepatocellular carcinoma after 5-year entecavir treatment than PAGE-B. J Dig Dis. 2023;24(2):113\u201321","journal-title":"J Dig Dis"},{"issue":"12","key":"11108_CR204","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1111\/liv.13938","volume":"38","author":"BG Kim","year":"2018","unstructured":"Kim BG, Park NH, Lee SB, Jeon S, Park JH, Jung SW, et al. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B. Liver Int. 2018;38(12):2269\u201376","journal-title":"Liver Int"},{"issue":"5","key":"11108_CR205","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/hep.29320","volume":"66","author":"GV Papatheodoridis","year":"2017","unstructured":"Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66(5):1444\u201353","journal-title":"Hepatology"},{"issue":"7","key":"11108_CR206","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","volume":"130","author":"BH Zhang","year":"2004","unstructured":"Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(7):417\u2013422","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"11108_CR207","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","volume":"77","author":"AG Singal","year":"2022","unstructured":"Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. J Hepatol. 2022;77(1):128\u201339","journal-title":"J Hepatol"},{"issue":"6","key":"11108_CR208","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3390\/biomedicines12061260","volume":"12","author":"E Tourkochristou","year":"2024","unstructured":"Tourkochristou E, Kalafateli M, Triantos C, Aggeletopoulou I. Evaluation of PAGE-B score for hepatocellular carcinoma development in chronic hepatitis b patients: reliability, validity, and responsiveness. Biomedicines. 2024;12(6):1260","journal-title":"Biomedicines"},{"issue":"1","key":"11108_CR209","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1053\/j.gastro.2019.02.049","volume":"157","author":"F Kanwal","year":"2019","unstructured":"Kanwal F, Singal AG. Surveillance for hepatocellular carcinoma: current best practice and future direction. Gastroenterology. 2019;157(1):54\u201364","journal-title":"Gastroenterology"},{"issue":"12","key":"11108_CR210","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","volume":"20","author":"AG Singal","year":"2023","unstructured":"Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20(12):864\u2013884","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"11108_CR211","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jhep.2010.03.010","volume":"53","author":"V Santi","year":"2010","unstructured":"Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53(2):291\u20137","journal-title":"J Hepatol"},{"issue":"6","key":"11108_CR212","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","volume":"154","author":"K Tzartzeva","year":"2018","unstructured":"Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology. 2018;154(6):1706\u201318 e1","journal-title":"Gastroenterology"},{"issue":"2","key":"11108_CR213","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2217\/hep.13.22","volume":"1","author":"M Sherman","year":"2014","unstructured":"Sherman M. Limitations of screening for hepatocellular carcinoma. Hepat Oncol. 2014;1(2):161\u2013163","journal-title":"Hepat Oncol"},{"issue":"1","key":"11108_CR214","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12885-021-08138-3","volume":"21","author":"H Feng","year":"2021","unstructured":"Feng H, Li B, Li Z, Wei Q, Ren L. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer. 2021;21(1):401","journal-title":"BMC Cancer"},{"issue":"5","key":"11108_CR215","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/jgh3.12720","volume":"6","author":"HL Chan","year":"2022","unstructured":"Chan HL, Vogel A, Berg T, De Toni EN, Kudo M, Trojan J, et al. Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis. JGH Open. 2022;6(5):292\u2013300","journal-title":"JGH Open"},{"issue":"2","key":"11108_CR216","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3350\/cmh.2022.0212","volume":"29","author":"BN Toan","year":"2023","unstructured":"Toan BN, Tan CK, Hasan I, Setiawan L, Yu ML, Izumi N, et al. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region. Clin Mol Hepatol. 2023;29(2):277\u201392","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"11108_CR217","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3233\/CBM-170551","volume":"21","author":"G Ricco","year":"2018","unstructured":"Ricco G, Cavallone D, Cosma C, Caviglia GP, Oliveri F, Biasiolo A, et al. Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers. Cancer Biomark. 2018;21(3):603\u201312","journal-title":"Cancer Biomark"},{"issue":"3","key":"11108_CR218","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jhep.2022.11.020","volume":"78","author":"TC Yip","year":"2023","unstructured":"Yip TC, Wong VW, Lai MS, Lai JC, Hui VW, Liang LY, et al. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss. J Hepatol. 2023;78(3):524\u201333","journal-title":"J Hepatol"},{"key":"11108_CR219","volume":"20","author":"R Diel","year":"2025","unstructured":"Diel R, Nienhaus A. Risk of Hepatitis B transmission by healthcare workers - a systematic review. GMS Hyg Infect Control. 2025;20: Doc43","journal-title":"GMS Hyg Infect Control"},{"issue":"RR-3","key":"11108_CR220","first-page":"1","volume":"61","author":"Centers for Disease C","year":"2012","unstructured":"Centers for Disease C, Prevention. Updated CDC recommendations for the management of Hepatitis B virus-infected health-care providers and students. MMWR Recomm Rep. 2012;61(RR-3):1\u201312","journal-title":"MMWR Recomm Rep"},{"issue":"3-4","key":"11108_CR221","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000360949","volume":"57","author":"WH Gerlich","year":"2014","unstructured":"Gerlich WH. Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy. Intervirology. 2014;57(3\u20134):202\u2013211","journal-title":"Intervirology"},{"issue":"10","key":"11108_CR222","first-page":"2181","volume":"51","author":"S Sabeena","year":"2022","unstructured":"Sabeena S, Ravishankar N. Horizontal modes of transmission of hepatitis B virus (HBV): a systematic review and meta-analysis. Iran J Public Health. 2022;51(10):2181\u20132193","journal-title":"Iran J Public Health"},{"key":"11108_CR223","volume-title":"A pilot survey of stigma related to infection with hepatitis B and C","author":"European Centre for Disease Prevention and Control","year":"2025","unstructured":"European Centre for Disease Prevention and Control. A pilot survey of stigma related to infection with hepatitis B and C. Stockholm: ECDC; 2025"},{"key":"11108_CR224","doi-asserted-by":"publisher","DOI":"10.2196\/66379","volume":"9","author":"BM Zimmermann","year":"2025","unstructured":"Zimmermann BM, Willem T, Rost M, Matthes N, Buyx A. Perceptions of stigma among patients with hepatitis B in Germany: cross-sectional survey. JMIR Form Res. 2025;9: e66379","journal-title":"JMIR Form Res"},{"issue":"5","key":"11108_CR225","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.gastrohep.2020.08.008","volume":"44","author":"A Yozgat","year":"2021","unstructured":"Yozgat A, Can G, Can H, Ekmen N, Akyol T, Kasapoglu B, et al. Social stigmatization in Turkish patients with chronic hepatitis B and C. Gastroenterol Hepatol. 2021;44(5):330\u20136","journal-title":"Gastroenterol Hepatol"},{"issue":"5","key":"11108_CR226","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/jvh.13932","volume":"31","author":"JG Katcher","year":"2024","unstructured":"Katcher JG, Klassen AC, Hann HW, Chang M, Juon HS. Racial discrimination, knowledge, and health outcomes: the mediating role of hepatitis B-related stigma among patients with chronic hepatitis B. J Viral Hepat. 2024;31(5):248\u2013254","journal-title":"J Viral Hepat"},{"key":"11108_CR227","doi-asserted-by":"publisher","first-page":"102818","DOI":"10.1016\/j.eclinm.2024.102818","volume":"76","author":"T Van Kim","year":"2024","unstructured":"Van Kim T, Pham TN, Phan P, Le MH, Le Q, Nguyen PT, et al. Effectiveness and implementation of decentralized, community- and primary care-based strategies in promoting hepatitis B testing uptake: a systematic review and meta-analysis. EClinicalMedicine. 2024;76:102818","journal-title":"EClinicalMedicine"},{"key":"11108_CR228","first-page":"101116","volume":"48","author":"K Hosking","year":"2024","unstructured":"Hosking K, Binks P, De Santis T, Wilson PM, Gurruwiwi GG, Bukulatjpi SM, et al. Evaluating a novel model of hepatitis B care, Hep B PAST, in the Northern Territory of Australia: results from a prospective, population-based study. Lancet Reg Health West Pac. 2024;48:101116","journal-title":"Lancet Reg Health West Pac"},{"issue":"3","key":"11108_CR229","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/tmi.13528","volume":"26","author":"M Muniyandi","year":"2021","unstructured":"Muniyandi M, Tyagi K, Singh M, Prakash V, Karikalan N, Senthilkumar S, et al. Economic evaluation of implementing a decentralised Hepatitis B virus diagnostic intervention under National Viral Hepatitis Control Programme in Tamil Nadu. South India Trop Med Int Health. 2021;26(3):374\u201384","journal-title":"South India. Trop Med Int Health"},{"key":"11108_CR230","first-page":"100737","volume":"35","author":"L Zhang","year":"2023","unstructured":"Zhang L, Liu H, Zou Z, Su S, Ong JJ, Ji F, et al. Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: reinterpreting the primary care and specialty divide. Lancet Reg Health West Pac. 2023;35:100737","journal-title":"Lancet Reg Health West Pac"},{"issue":"2","key":"11108_CR231","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","volume":"4","author":"GS Cooke","year":"2019","unstructured":"Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4(2):135\u201384","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"11108_CR232","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S2468-1253(25)00163-3","volume":"10","author":"AJ Stockdale","year":"2025","unstructured":"Stockdale AJ, Holt B, Bhadoria AS, Sadasivan A, Ikeda D, Pollack T, et al. Service delivery models and care cascade outcomes for people living with chronic hepatitis B: a global systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025;10(11):1013\u201327","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"11108_CR233","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41124-017-0031-2","volume":"3","author":"DA O\u2019Leary","year":"2018","unstructured":"O\u2019Leary DA, Cropp E, Isaac D, Desmond PV, Bell S, Nguyen T, et al. \u201cB in IT\u201d - a community-based model for the management of hepatitis B patients in primary care clinics using a novel web-based clinical tool. Hepatol Med Policy. 2018;3:1","journal-title":"Hepatol Med Policy"},{"issue":"3","key":"11108_CR234","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1053\/gast.2002.31887","volume":"122","author":"GK Lau","year":"2002","unstructured":"Lau GK, Suri D, Liang R, Rigopoulou EI, Thomas MG, Mullerova I, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology. 2002;122(3):614\u201324","journal-title":"Gastroenterology"},{"issue":"1","key":"11108_CR235","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jhep.2024.02.017","volume":"81","author":"BC Narmada","year":"2024","unstructured":"Narmada BC, Khakpoor A, Shirgaonkar N, Narayanan S, Aw PP, Singh M, et al. Single-cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity. J Hepatol. 2024;81(1):42\u201361","journal-title":"J Hepatol"},{"issue":"12","key":"11108_CR236","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1111\/jgh.16728","volume":"39","author":"LY Mak","year":"2024","unstructured":"Mak LY, Hui RW, Chung MS, Wong DK, Fung J, Seto WK, et al. Regression of liver fibrosis after HBsAg loss: A prospective matched case-control evaluation using transient elastography and serum enhanced liver fibrosis test. J Gastroenterol Hepatol. 2024;39(12):2826\u201334","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"11108_CR237","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.gastha.2023.06.004","volume":"2","author":"E Morais","year":"2023","unstructured":"Morais E, Mason L, Dever J, Martin P, Chen JV, Felton L, et al. Clinical Consequences of Hepatitis B Surface Antigen Loss in Chronic Hepatitis B Infection: A Systematic Literature Review and Meta-Analysis. Gastro Hep Adv. 2023;2(7):992\u20131004","journal-title":"Gastro Hep Adv"},{"issue":"1","key":"11108_CR238","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/apt.16659","volume":"55","author":"A Vittal","year":"2022","unstructured":"Vittal A, Sharma D, Hu A, Majeed NA, Terry N, Auh S, et al. Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2022;55(1):8\u201325","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"11108_CR239","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.25047","volume":"15","author":"Q Sheng","year":"2018","unstructured":"Sheng Q, Ding Y, Li B, Han C, Li Y, Zhang C, et al. Efficacy and safety of nucleos(t)ide analogues to prevent hepatitis B virus mother-to-child transmission in pregnant women with high viremia: real life practice from China. Int J Med Sci. 2018;15(8):796\u2013801","journal-title":"Int J Med Sci"},{"issue":"10","key":"11108_CR240","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.cgh.2018.02.037","volume":"16","author":"MG Ghany","year":"2018","unstructured":"Ghany MG, Pan CQ, Lok AS, Feld JJ, Lim JK, Wang SH, et al. Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient-Reported Outcomes. Clin Gastroenterol Hepatol. 2018;16(10):1641\u20139 e6","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"11108_CR241","first-page":"534","volume":"33","author":"Author Group of Expert O","year":"2025","unstructured":"Author Group of Expert O. [Expert opinions on the technical guiding principles for clinical trials of drugs in the treatment of chronic hepatitis B virus infection]. Zhonghua Gan Zang Bing Za Zhi. 2025;33(6):534\u2013544","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"4","key":"11108_CR242","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1097\/HEP.0000000000001549","volume":"83","author":"MG Ghany","year":"2025","unstructured":"Ghany MG, Pan CQ, Lok AS, Feld JJ, Lim JK, Wang SH, et al. AASLD\/IDSA Practice Guideline on treatment of chronic hepatitis B. Hepatology. 2025;83(4):974\u2013997","journal-title":"Hepatology"},{"issue":"2","key":"11108_CR243","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","volume":"83","author":"European Association for the Study of the L","year":"2025","unstructured":"European Association for the Study of the L. EASL clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502\u2013583","journal-title":"J Hepatol"},{"issue":"6","key":"11108_CR244","first-page":"1425","volume":"11","author":"H You","year":"2023","unstructured":"You H, Wang FS, Li T, Xu X, Sun Y, Nan Y, et al. Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022). J Clin Transl Hepatol. 2023;11(6):1425\u201342","journal-title":"J Clin Transl Hepatol"},{"issue":"10","key":"11108_CR245","doi-asserted-by":"publisher","first-page":"101510","DOI":"10.1016\/j.jhepr.2025.101510","volume":"7","author":"J Dana","year":"2025","unstructured":"Dana J, Meyer A, Paisant A, Rode A, Sartoris R, S\u00e9ror O, et al. Improving risk stratification and detection of early HCC using ultrasound-based deep learning models. JHEP Rep. 2025;7(10):101510","journal-title":"JHEP Rep"},{"issue":"5","key":"11108_CR246","first-page":"1184","volume":"11","author":"S Feng","year":"2023","unstructured":"Feng S, Wang J, Wang L, Qiu Q, Chen D, Su H, et al. Current Status and Analysis of Machine Learning in Hepatocellular Carcinoma. J Clin Transl Hepatol. 2023;11(5):1184\u201391","journal-title":"J Clin Transl Hepatol"},{"issue":"3","key":"11108_CR247","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1053\/j.gastro.2025.05.012","volume":"169","author":"A Spann","year":"2025","unstructured":"Spann A, Strauss AT, Davis SE, Bhat M. The role of artificial intelligence in chronic liver diseases and liver transplantation. Gastroenterology. 2025;169(3):456\u2013470","journal-title":"Gastroenterology"},{"issue":"3","key":"11108_CR248","doi-asserted-by":"publisher","first-page":"100441","DOI":"10.1016\/j.jhepr.2022.100441","volume":"4","author":"GL Wong","year":"2022","unstructured":"Wong GL, Hui VW, Tan Q, Xu J, Lee HW, Yip TC, et al. Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis. JHEP Rep. 2022;4(3):100441","journal-title":"JHEP Rep"},{"issue":"1","key":"11108_CR249","doi-asserted-by":"publisher","first-page":"2314237","DOI":"10.1080\/07853890.2024.2314237","volume":"56","author":"W Dong","year":"2024","unstructured":"Dong W, Da Roza CC, Cheng D, Zhang D, Xiang Y, Seto WK, et al. Development and validation of HBV surveillance models using big data and machine learning. Ann Med. 2024;56(1):2314237","journal-title":"Ann Med"},{"issue":"4","key":"11108_CR250","volume":"16","author":"M Elhaddad","year":"2024","unstructured":"Elhaddad M, Hamam S. AI-driven clinical decision support systems: an ongoing pursuit of potential. Cureus. 2024;16(4): e57728","journal-title":"Cureus"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11108-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11108-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11108-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:01:54Z","timestamp":1787763714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-026-11108-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":250,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["11108"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11108-1","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"13 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H You has served as a consultant or advisory board member for GSK; R Maiwall received investigator-initiated research grants from Takeda; YJ Kim received research support from AstraZeneca, Boston Scientific, Daewoong, Yuhan, has served as a consultant of AstraZeneca, Eisai, Boehringer Ingelheim, and a speaker of Samil, Celltion; George Boon-Bee Goh has served as a consultant or advisory board member for Roche, Boehringer Ingelheim, MSD and Novo Nordisk; and a speaker for Echosens, Viatris and Abbott; ML\u00a0Yu\u00a0received research support from Abbvie, Abbott Diagnostic, BMS, Gilead, Merck,\u00a0Novo Nordisc and Roche diagnostics, has served as a consultant of Abbvie, Abbott Diagnostic, BMS, Gilead,\u00a0Novo Nordisc, Roche and Roche diagnostics, and a speaker of Abbvie, BMS, Eisai, Gilead, Roche and Roche diagnostics; GLH Wong received a research grant from Gilead Sciences, has served as an advisory committee member for AstraZeneca, Gilead Sciences, and Janssen, and as a speaker for Abbott, AbbVie, Ascletis, Bristol-Myers Squibb, Echosens, Gilead Sciences, Janssen, and Roche; VWS Wong has served as a consultant or advisory committee member for AbbVie, Boehringer Ingelheim, Echosens, Intercept, Inventiva, Novo Nordisk, Pfizer, and TARGET PharmaSolutions; and a speaker for Abbott, AbbVie, Gilead Sciences, and Novo Nordisk. He has received a research grant from Gilead Sciences, and is a cofounder of Illuminatio Medical Technology Limited; TCF Yip has served as an advisory committee member and a speaker for Gilead Sciences; Q Ning has served as a consultant or advisory committee member as well as a speaker for GSK, Gilead; L Wei has received research grants from Abbvie, Bristol-Myers Squibb, and Gilead, and consulting for Gilead, Huahui, MSD, Pfizer, speaker for Ascletis Pharma, Bristol-Myers Squibb, Gilead, and Kaiyin; M Otsuka has received research grants from AstraZeneca and has served as a speaker for Gilead; A Thompson has received consulting fees from Gilead, Abbvie, Roche Diagnostics, Assembly Biosciences, speaker fees from Gilead Sciences, Roche Diagnostics and investigator-initiated grants from Gilead Sciences; G Lau\u00a0has served as a consultant for AstraZeneca. Other authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}